Upper Extremity Deep Venous Thrombosis in Cancer Patients with Venous Access Devices - Prophylaxis with a Low Molecular Weight Heparin (Fragmin)

Summary

Central venous access devices are often essential for the administration of chemotherapy to patients with malignancy, but its use has been associated with a number of complications, mainly thrombosis. The true incidence of upper extremity deep vein thrombosis (DVT) in this setting is difficult to estimate since there are very few studies in which DVT diagnosis was based on objective tests, but its sequelae include septic thrombophlebitis, loss of central venous access and pulmonary embolism.

We performed an open, prospective study in which all cancer patients who underwent placement of a long-term Port-a-Cath (Pharmacia Deltec Inc) subclavian venous catheter were randomized to receive or not 2500 IU sc of Fragmin once daily for 90 days. Venography was routinely performed 90 days after catheter insertion, or sooner if DVT symptoms had appeared. Our aims were: 1) to investigate the effectiveness of low doses of Fragmin in preventing catheter-related DVT; and 2) to try to confirm if patients with high platelet counts are at a higher risk to develop subclavian DVT, as previously suggested.

On the recommendation of the Ethics Committee, patient recruitment was terminated earlier than planned: DVT developed in 1/16 patients (6%) taking Fragmin and 8/13 patients (62%) without prophylaxis (Relative Risk 6.75; 95% Cl: 1.05-43.58; p = 0.002, Fisher exact test). No bleeding complications had developed. As for prediction of DVT, there was a tendency towards a higher platelet count in those patients who subsequently developed DVT, but differences failed to reach any statistical significance (286 ±145 vs 207 ±81 X 10⁹/1; p = 0.067). According to our experience, Fragmin at the dosage used proved to be both effective and safe in these patients.

• References

• 1 Hill SL, Berry RE. Subclavian vein thrombosis: A continuing challenge. Surgery 1990; 108: 1-9
• 2 Wechsler RJ, Spirn PW, Conant EF, Steiner RF, Needleman L. Thrombosis and infection caused by thoracic venous catheters: Pathogenesis and imaging findings. AJR 1993; 160: 467-471
• 3 Haire WD, Lieberman RP, Edney J, Vaughan WP, Kessinger A, Armitage JO, Goldsmith JC. Hickman catheter-induced thoracic vein thrombosis. Frequency and long-term sequelae in patients receiving high-dose chemotherapy and marrow transplantation. Cancer 1990 66. 900-908
• 4 Monreal M, Lafoz E, Casals A, Ruiz J, Arias A. Platelet count and venous thromboembolism. A useful test for suspected pulmonary embolism. Chest 1991; 100: 1493-1496
• 5 Monreal M, Lafoz E, Ruiz J, Gimenez G. Platelet count in acute pulmonary embolism: its relationship to recurrences. Haemostasis 1993; 23: 263-268
• 6 Monreal M, Lafoz E, Roca J, Granero X, Soler J, Salazar X, Olazabal A, Bergqvist D. Platelet count, antiplatelet therapy and pulmonary embolism. A prospective study in patients with hip surgery. Thromb Haemost 1995 73. 380-385
• 7 Alastrue A, Rull M, Escudero LE, Moral P, Gelonch J, Carles J, Flores A, Rosell R, Broggi MA. Experiencia con 150 reservorios venosos subcu-taneos como acceso venoso e infusion de tratamiento en pacientes adultos oncologicos, hematologicos y afectos de smdrome de inmunodeficiencia adquirida. Med Clin 1992; 99: 444-449
• 8 Gelonch J, Alastrue A, Ribera JM. Reservorios venosos subcutaneos. Med Clin 1992; 99: 465-470
• 9 Horattas MC, Wright DJ, Fenton AH, Evans DM, Oddi MA, Kamienski RW, Shields EF. Changing concepts of deep venous thrombosis of the upper extremity. Report of a series and review of the literature. Surgery 1988; 104: 561-567
• 10 Monreal M, Lafoz E, Ruiz J, Vails R, Alastrue A. Upper extremity deep-venous thrombosis and pulmonary embolism. A prospective study. Chest 1991; 99: 280-567
• 11 Monreal M, Raventos A, Lerma R, Ruiz J, Lafoz E, Alastrue A, Llama-zares JF. Pulmonary embolism in patients with upper-extremity DVT associated to venous central lines. A prospective study. Thromb Haemost 1994; 72 (04) 548-550
• 12 Anderson AJ, Krasnow SH, Boyer MW, Cutler DJ, Jones BD, Citron ML, Ortega LG, Cohen MH. Thrombosis: the major Hickman catheter complication in patients with solid tumor. Chest 1989; 95 (71) 19-25
• 13 Starkhammar H, Bengtsson M, Morales O. Fibrin sleeve formation after long term brachial catheterisation with an implantable port device. A prospective venographic study. Eur J Surg 1992; 158: 481-488
• 14 Home MDK, Mayo DJ, Alexander R, Steinhaus EP, Chang RC, Whitman E, Gralnick HR. Upper extremity impedance plethysmography in patients with venous access devices. Thromb Haemost 1994; 72: 540-215
• 5 Bern MM, Lokich JJ, Wallach SR, Bothe A, Benotti PN, Arkin CF, Greco FA, Huberman M, Moore C. Very low doses of warfarin can prevent thrombosis in central venous catheters. A randomized prospective trial. Ann Intern Med 1990; 112: 423-428
• 16 Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, Samosh M, Bramwell V, Pritchard K, Stewart D, Goodwin P. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-889